These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19089662)

  • 1. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
    Ali CW; Kaye TF; Adamson DJ; Tait IS; Polignano FM; Highley MS
    J Gastrointest Cancer; 2007; 38(2-4):108-14. PubMed ID: 19089662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
    Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
    Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma.
    Lee BS; Lee SH; Son JH; Jang DK; Chung KH; Paik WH; Ryu JK; Kim YT
    J Gastroenterol Hepatol; 2016 Feb; 31(2):493-500. PubMed ID: 26220764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine.
    Petekkaya I; Gezgen G; Roach EC; Solak M; Gullu I
    J BUON; 2012; 17(4):796. PubMed ID: 23335544
    [No Abstract]   [Full Text] [Related]  

  • 6. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.
    Kobayashi H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Ann Surg; 2012 Aug; 256(2):288-96. PubMed ID: 22580938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
    Vogl TJ; Schwarz W; Eichler K; Hochmuth K; Hammerstingl R; Jacob U; Scheller A; Zangos S; Heller M
    J Cancer Res Clin Oncol; 2006 Nov; 132(11):745-55. PubMed ID: 16858591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
    Hess V; Glimelius B; Grawe P; Dietrich D; Bodoky G; Ruhstaller T; Bajetta E; Saletti P; Figer A; Scheithauer W; Herrmann R
    Lancet Oncol; 2008 Feb; 9(2):132-8. PubMed ID: 18249033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External beam radiation therapy with or without concurrent chemotherapy for patients with unresectable locally advanced hilar cholangiocarcinoma.
    Chen SC; Chen MH; Li CP; Chen MH; Chang PM; Liu CY; Tzeng CH; Liu YM; Yen SH; Chao Y; Huang PI
    Hepatogastroenterology; 2015; 62(137):102-7. PubMed ID: 25911877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
    Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
    Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
    Halm U; Schumann T; Schiefke I; Witzigmann H; Mössner J; Keim V
    Br J Cancer; 2000 Mar; 82(5):1013-6. PubMed ID: 10737382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
    Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
    Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features of long time survivors with unresectable pancreatic cancer treated by gemcitabine alone].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Fujisawa N; Yoneda M; Abe Y; Inamori M; Kawamura H; Kirikoshi H; Shimamura T; Kubota K; Sakaguchi T; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):207-12. PubMed ID: 16484857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-surviving patient with hilar cholangiocarcinoma by gemcitabine monotherapy].
    Iwata N; Yoshida T; Katsuta E; Aoyagi H; Takahata T; Hasegawa K; Kaneko J; Maejima S
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2116-8. PubMed ID: 23267995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
    JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
    Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
    Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
    Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma.
    Diaz CL; Cinar P; Hwang J; Ko AH; Tempero MA
    Am J Clin Oncol; 2019 Dec; 42(12):898-902. PubMed ID: 31634155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
    Rocha Lima CM; Savarese D; Bruckner H; Dudek A; Eckardt J; Hainsworth J; Yunus F; Lester E; Miller W; Saville W; Elfring GL; Locker PK; Compton LD; Miller LL; Green MR
    J Clin Oncol; 2002 Mar; 20(5):1182-91. PubMed ID: 11870159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Sakabe R; Ohge H; Sueda T
    Ann Surg Oncol; 2011 Mar; 18(3):651-8. PubMed ID: 20945107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.